{"id":1226,"date":"2002-09-01T12:08:00","date_gmt":"2002-09-01T10:08:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/risikoreduktion-durch-simvastatin-bei-arteriosklerose-die-mrc-bhf-heart-protection-study"},"modified":"2022-03-17T14:10:10","modified_gmt":"2022-03-17T13:10:10","slug":"risikoreduktion-durch-simvastatin-bei-arteriosklerose-die-mrc-bhf-heart-protection-study","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/risikoreduktion-durch-simvastatin-bei-arteriosklerose-die-mrc-bhf-heart-protection-study","title":{"rendered":"Risikoreduktion durch Simvastatin bei Arteriosklerose. Die MRC\/BHF Heart Protection Study"},"content":{"rendered":"<p>Wieder einmal haben britische Forscher Studienergebnisse ver\u00f6ffentlicht, die zu einem Meilenstein in der Pharmakotherapie werden k\u00f6nnten. Weitgehend unabh\u00e4ngig von industriellem Sponsoring organisierten das Medical Research Council (MRC) und die British Heart Foundation (BHF) die Heart Protection Study (HPS), die in zwei Teilen im Juli 2002 im Lancet ver\u00f6ffentlicht wurde (Lancet 2002, 360, 7und 2002, 360, [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wieder einmal haben britische Forscher Studienergebnisse ver\u00f6ffentlicht, die zu einem Meilenstein in der Pharmakotherapie werden k\u00f6nnten. Weitgehend unabh\u00e4ngig von industriellem Sponsoring organisierten das Medical Research Council (MRC) und die British Heart Foundation (BHF) die Heart Protection Study (HPS), die in zwei Teilen im Juli 2002 im Lancet ver\u00f6ffentlicht wurde (Lancet 2002, 360, 7und 2002, 360, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2265,60,3027,3028,451,449,71,68,455,2315,453,498,456,2314,65,3029,56,505,443,2261,2260,2262],"class_list":["post-1226","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-alpha-tocopherol","tag-apoplektischer-insult","tag-betacaroten","tag-betacarotin","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-herzinfarkt","tag-hirninfarkt","tag-hmg-coa-reduktase-hemmer","tag-hps-studie","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-mrc-bhf-hps-studie","tag-myokardinfarkt","tag-provitamin-a","tag-schlaganfall","tag-simvastatin","tag-statine","tag-tocopherol","tag-vitamin-c","tag-vitamin-e"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1226"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1226\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}